ImCheck ex-CEO on ASCO Oncology Trends, $1.2B Exit and French Biotech | Pierre d’Epenoux | E60

<p>After ImCheck’s inception in 2015, Pierre took the helm through clinical development and guided the startup to a $1.2B buyout by Ipsen in 2025.</p><p>In a session at the Kadans Oncology Summit, he talks about how the exit materialised and the oncology space, including highlights from ASCO 2026, ADCs, in vivo CAR-T &amp; checkpoint inhibitors. </p><p>He reveals some of the most shocking lessons he learned from his time at Imcheck.</p><p>---Learn more about Kadans’ Oncology Clusters, where oncology biotechs grow from start-up to global player: <a href="https://bit.ly/kadans-oncology" target="_blank" rel="ugc noopener noreferrer">https://bit.ly/kadans-oncology</a>---</p><p>⭐️ ABOUT THE SPEAKERPierre has 30 years of experience in the biopharmaceutical industry, including 9 years at ImCheck and more than 3 years as EVP, Chief Strategy Officer at Theravectys. Prior to this, he also spent 10 years in senior roles in Sanofi and Baxter Healthcare.</p><p>🔗 LINKS MENTIONED</p><ul><li>Kadans Oncology Summit — <a href="https://www.kadansoncologysummit.com/" target="_blank" rel="ugc noopener noreferrer">https://www.kadansoncologysummit.com/</a></li><li>ImCheck Therapeutics — <a href="https://www.imchecktherapeutics.com/" target="_blank" rel="ugc noopener noreferrer">https://www.imchecktherapeutics.com/</a></li><li>ImCheck ASCO data (2025) — <a href="https://www.imchecktherapeutics.com/all-press-release/news/imcheck-reports-high-remission-rates-in-aml-patients-with-ict01-combination-therapy-at-asco-2025/" target="_blank" rel="ugc noopener noreferrer">https://www.imchecktherapeutics.com/all-press-release/news/imcheck-reports-high-remission-rates-in-aml-patients-with-ict01-combination-therapy-at-asco-2025/</a></li><li>ImCheck acquisition by Ipsen (2025) — <a href="https://www.ipsen.com/press-release/ipsen-to-acquire-imcheck-therapeutics-expanding-its-leadership-in-oncology-strengthening-its-pipeline-3170788/" target="_blank" rel="ugc noopener noreferrer">https://www.ipsen.com/press-release/ipsen-to-acquire-imcheck-therapeutics-expanding-its-leadership-in-oncology-strengthening-its-pipeline-3170788/</a></li><li>Pancreatic cancer ASCO data (2026) — <a href="https://www.asco.org/about-asco/press-center/multi-selective-ras-inhibitor-nearly-doubles-survival-pancreatic-cancer" target="_blank" rel="ugc noopener noreferrer">https://www.asco.org/about-asco/press-center/multi-selective-ras-inhibitor-nearly-doubles-survival-pancreatic-cancer</a></li><li>Dominik Schumacher, Tubulis | Founder-led ADC Biotech | E19 — <a href="https://flot.bio/episode/dominik-schumacher-tubulis/" target="_blank" rel="ugc noopener noreferrer">https://flot.bio/episode/dominik-schumacher-tubulis/</a></li><li>Ona Therapeutics raises $86.6M — <a href="https://ona-therapeutics.com/press-release/ona-therapeutics-raises-86m/" target="_blank" rel="ugc noopener noreferrer">https://ona-therapeutics.com/press-release/ona-therapeutics-raises-86m/</a></li><li>Moderna five-year cancer-vaccine data (2026) — <a href="https://www.merck.com/news/moderna-merck-announce-5-year-data-for-intismeran-autogene-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-the-primary-endpoint-of-recurrence-free-survival-i/" target="_blank" rel="ugc noopener noreferrer">https://www.merck.com/news/moderna-merck-announce-5-year-data-for-intismeran-autogene-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-the-primary-endpoint-of-recurrence-free-survival-i/</a></li><li>Sean Marett | BioNTech, Art of Dealmaking | E25 — <a href="https://flot.bio/episode/sean-marett-biontech-dealmaking/" target="_blank" rel="ugc noopener noreferrer">https://flot.bio/episode/sean-marett-biontech-dealmaking/</a></li><li>Laurent Levy, Nanobiotix | Nanoparticles, Radiotherapy | E45— <a href="https://flot.bio/episode/laurent-levy-nanobiotix-nanoparticles-radiotherapy/" target="_blank" rel="ugc noopener noreferrer">https://flot.bio/episode/laurent-levy-nanobiotix-nanoparticles-